Stanford University Library homepage Stanford Web Archive Portal Home | Help
Showing http://web.stanford.edu/group/pawender/drug-design-and-evaluation.html captured on Sep 20, 2015
Previous capture | Hide overlay | Next capture

Captured 37 times between June 21, 2015 and April 29, 2022

Year
1991 1995 2000 2005 2010 2014
Month
Jan Apr Aug Dec
Day
1st 5th 10th 15th 20th 25th 30th
  • Home
  • About Professor Wender
  • Group Members
  • Publications
    • New Reaction Development
    • Total Synthesis
    • Drug Design and Evaluation
    • Drug Delivery Systems
    • PKC and Receptors
    • Other Items
  • Research
    • Function Oriented Synthesis
    • New Therapies and Drugs
    • Drug Delivery
    • New Reaction Development
  • Media
  • Contact Us

Drug Design, Synthesis, and Biological Evaluation
Previous   Next

  • Wender, Paul; Quiroz, Ryan; Stevens, Matthew; "Function Through Synthesis-Informed Design", Acc. Chem. Res.; 2015, 48(3), 752-760. Abstract, PDF.
  • Loy BA, Lesser AB, Staveness D, Billingsley KL, Cegelski L, Wender PA., "Toward a biorelevant structure of protein kinase C bound modulators: design, synthesis, and evaluation of labeled bryostatin analogues for analysis with rotational echo double resonance NMR spectroscopy", J Am Chem Soc., 2015, 137(10), 3678-3685. Abstract, PDF, Supporting Information.
  • Paul A. Wender and Daryl Staveness; "Improved Protein Kinase C Affinity through Final Step Diversification of Simplified Salicylate-Derived Bryostatin Analog Scaffold", Organic Letters, 2014, 16(19), 5140-5143. Abstract, PDF.
  • Wender, Paul; Nakagawa, Yu; Near, Katherine; Staveness, Daryl; "Computer-Guided Design, Synthesis, and Protein Kinase C Affinity of a New Salicylate-Based Class of Bryostatin Analogs", Organic Letters, 2014, 16(19), 5136-5139. Abstract, PDF.
  • Wender, P.A.; Axtman, A.D.; Golden, J..; Kee, J.-M.; Sirois, L.E.; Quiroz, R.V.; Stevens, M.C.; "Function through Bio-Inspired, Synthesis-Informed Design: Step-Economical Synthesis of Designed Kinase Inhibitors", Organic Chemistry Frontiers, 2014, 1, 1166-1171. Abstract, PDF.
  • Wender, P.A., “Toward the Ideal Synthesis and Molecular Function through Synthesis-informed Design; Natural Products Reports, 2014, 31, 433-440. PDF.
  • Wender, P.A.; Donnelly, A.C.; Loy, B.A.; Near, K.E.; Staveness, D., “Rethinking the Role of Natural Products: Function-Oriented Synthesis, Bryostatin and Bryologs;Natural Products in Medicinal Chemistry (Ed: S. Hanessian) Wiley-VCH, 2014, Ch. 14, 475-544. PDF.
  • Brian A. DeChristopher, Brian A. Loy, Matthew D. Marsden, Adam J. Schrier, Jerome A. Zack, & Paul A. Wender, “Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro”, Nature Chemistry, 2012, 4, 705-710. Full Text.
  • DeChristopher, Brian A., Fan, A.C., Felsher, D.W., Wender, Paul A., “”Picolog,” a Synthetically-Available Bryostatin Analog, Inhibits Growth of MYC-Induced Lymphoma in Vivo”; Oncotarget, 2012, 3(1), 58-66. Abstract, PDF, Full Text.
  • Wender, P. A.; Baryza, J. L.; Brenner, S. E.; DeChristopher, B. A.; Loy, B. A.; Schrier, A. J.; Verma, V. A. "Function-Oriented Synthesis: Design, Synthesis and Evaluation of Potent Bryostatin Analogs that Modulate PKC Translocation Selectivity." Proc. Natl. Acad. Sci. USA. 2011, 108, 6721-6726. Abstract, PDF, Supporting Information.
  • Wender, P. A.; Loy, B. A.; Schrier, A. J. "Translating Nature's Library: the Bryostatins and Function-Oriented Synthesis." Isr. J. Chem. 2011, 51, 453-472. Abstract, PDF.
  • Wender, Paul A.; Longcore, Kate E.; “Apoptolidins E and F, New Glycosyated Macrolactones Isolated from Nocardopsis sp.” Organic Letters, 2009, 5474-5477. Abstract, PDF, Supporting Information.
  • Wender, Paul A.; Miller, Benjamin L.; "Synthesis at the Molecular Frontier", Nature, 2009, 460, 197-201. Abstract, PDF.
  • Lewis, Chad A.; Longcore, Kate E.; Miller, Scott J.; Wender, Paul A. “An Approach to the Site-Selective Diversification of Apoptolidin A with Peptide-Based Catalysts”, Journal of Natural Products, 2009, 72(10), 1864-1869. Abstract , PDF , Supporting Information.
  • Mooberry, Susan; Hilinski, Michael; Clark, Erin; and Wender, Paul “Function-Oriented Synthesis: Biological Evaluation of Laulimalide Analogues Derived from a Last Step Cross Metathesis Diversification Strategy” Molecular Pharmaceutics; 2008; 5, 829-838. Abstract, PDF.
  • Wender, P.A.; DeChristopher, B.A.; Schrier, A.J. "Efficient Synthetic Access to a New Family of Highly Potent Bryostatin Analogues via a Prins-Drive Macrocyclization Strategy", J. Am. Chem. Soc.; 2008; 130(21); 6658-6659. Abstract, PDF, Supporting Information.
  • Wender, P. A.; Verma, V. A. “The Design, Synthesis, and Evaluation of C7 Diversified Bryostatin Analogs Reveals a Hot Spot for PKC Affinity,”Org. Lett. 2008, 10, 3331. Abstract, Supporting Information.
  • Wender, Paul A.; Verma, Vishal A.; Paxton, Thomas J.; Pillow, Thomas H. "Function Oriented Synthesis, Step Economy, and Drug Design", Accts. Chem. Res. 2008, 40-49. Abstract, PDF.
  • Wender, P. A.; Longcore, K. E. "Isolation, Structure Determination, and Anti-Cancer Activity of Apoptolidin D" Org. Lett. 2007, 9, 691-694.Abstract, PDF, Supporting Information.
  • Wender, P. A.; Baryza, J. L.; Hilinski, M. K.; Horan, J. C.; Kan, C.; Verma, V. A. In Drug Discovery Research: New Frontiers in the Post-Genomic Era; Huang, Z.; Ed.; Wiley-VCH: 2007. Abstract.
  • Wender, P. A.; Horan, J. C.; Verma, Vishal A. "Total Synthesis and Initial Biological Evaluation of New B-Ring-Modified Bryostatin Analogues"Org. Lett. 2006, 8, 5299-5302. Abstract, PDF, Supporting Information.
  • Wender, P. A.; Horan, J. C. "Synthesis and PKC Binding of a New Class of A-Ring Diversifiable Bryostatin Analogues Utilizing a Double Asymmetric Hydrogenation and Cross-Coupling Strategy" Org. Lett. 2006, 8, 4581-4584. Abstract, PDF, Supporting Information.
  • Wender, P. A.; Hilinski, M. K.; Skaanderup, P. R.; Soldermann, N. G.; Mooberry, S. L. "Pharmacophore mapping in the laulimalide series: total synthesis of a vinylogue for a late-stage metathesis diversification strategy" Org. Lett. 2006, 8, 4105-4108. Abstract, PDF, Supporting Information.
  • Clark, E. A.; Hills, P. M.; Davidson, B. S.; Wender, P. A.; Mooberry, S. L. "Laulimalide and synthetic laulimalide analogues are synergisitic with paclitaxel and 2-methoxyestradiol" Molecluar Pharmaceutics 2006, 3, 457-467. Abstract, PDF.
  • Wender, P. A.; Verma, V. A. "Design, Synthesis, and Biological Evaluation of a Potent, PKC Selective, B-Ring Analog of Bryostatin" Org. Lett.2006, 8, 1893-1896. Abstract, PDF, Supporting Information.
  • Wender, P. A.; Hilinski, M. K.; Soldermann, N.; Mooberry, S. L. "Total Synthesis and Biological Evaluation of 11-Desmethyllaulimalide, a Highly Potent Simplified Laulimalide Analogue" Org. Lett. 2006, 8, 1507-1510. Abstract, PDF, Supporting Information.
  • Wender, P. A.; Jankowski, O. D.; Longcore, K.; Tabet, E. A.; Seto, H.; Tomikawa, T. "Correlation of F0F1-ATPase Inhibition and Antiproliferative Activity of Apoptolidin Analogues" Org. Lett. 2006, 8, 589-592. Abstract, PDF, Supporting Information.
  • Wender, P. A.; Sukopp, M.; Longcore, K. "Apoptolidins B and C: Isolation, Structure Determination, and Biological Activity" Org. Lett. 2005, 7, 3025-3028. Abstract, PDF, Supporting Information.
  • Wender, P. A.; Clarke, M. O.; Horan, J. C. "Role of the A-Ring of Bryostatin Analogues in PKC Binding: Synthesis and Initial Biological Evaluation of New A-Ring-Modified Bryologs" Org. Lett. 2005, 7, 1995-1998. Abstract, PDF, Supporting Information.
  • Wender, P. A.; Baryza, J. L. "Identification of a Tunable Site in Bryostatin Analogs: C20 Bryologs Through Late Stage Diversification" Org. Lett.2005, 7, 1177-1180. Abstract, PDF, Supporting Information.
  • Wender, P. A.; Hilinski, M. K.; Mayweg, A. V. W. "Late-stage Intermolecular C-H Activation for Lead Diversification: A Highly Chemoselective Oxyfunctionalization of the C-9 Position of Potent Bryostatin Analogues" Org. Lett. 2005, 7, 79-82 Abstract, PDF, Supporting Information.
  • Wender, P. A.; Baryza, J. L.; Brenner, S. E.; Clarke, M. O.; Craske, M. L.; Horan, J. C.; Meyer, T. "Function Oriented Synthesis: The Design, Synthesis, PKC Binding and Translocation Activity of a New Bryostatin Analog." Curr. Drug Disc. Tech., 2004; 1, 1-11. Abstract.
  • Mooberry, S. L.; Randall-Hlubek, D. A.; Leal, R. M.; Hegde, S. G.; Hubbard, R. D.; Zhang, L.; Wender, P. A. "Microtubule-Stabilizing Agents Based on Designed Laulimalide Analogues" Proc. Natl. Acad. Sci. U. S. A., 2004, 101, 8803-8808. Abstract, PDF
  • Wender, P. A.; Hegde, S. G.; Hubbard, R. D.; Zhang, L.; Mooberry, S. L. "Synthesis and Biological Evaluation of (-)-Laulimalide Analogues" Org. Lett., 2003, 5, 5307-5309. Abstract, PDF, Supporting Information
  • Wender, P. A.; Jankowski, O. D.; Tabet, E. A.; Seto, H. "Facile Synthetic Access to and Biological Evaluation of the Macrocyclic Core of Apoptolidin " Org. Lett., 2003, 5, 2299-2302. Abstract, PDF, Supporting Information
  • Wender, P. A.; Baryza, J. L.; Brenner, S. E.; Clarke, M. O.; Gamber, G. G.; Horan, J. C.; Jessop, T. C.; Kan, C.; Pattabiraman, K.; Williams, T. J. "Inspirations from Nature. New Reactions, New Therapeutic Leads, and New Drug Delivery Systems" Pure Appl. Chem., 2003, 75, 143-156.Abstract.
  • Wender, P. A.; Mayweg, A. V. W.; VanDeusen, C. L. "A Concise, Selective Synthesis of the Polyketide Spacer Domain of a Potent Bryostatin Analogue" Org. Lett., 2003; 5, 277-279. Abstract, PDF, Supporting Information
  • Wender, P. A.; Jankowski, O. D.; Tabet, E. A.; Seto, H. "Toward a Structure-Activity Relationship for Apoptolidin: Selective Functionalization of the Hydroxyl Group Array" Org. Lett., 2003; 5, 487-490. Abstract, PDF, Supporting Information
  • Wender, P. A.; Baryza, J.; Bennett, C.; Bi, C.; Brenner, S. E.; Clarke, M.; Horan, J.; Kan, C.; Lacote, E.; Lippa, B.; Nell, P.; Turner, T. "The Practical Synthesis of a Novel and Highly Potent Analog of Bryostatin" J. Am. Chem. Soc. 2002, 124, 13648-13649. Abstract, PDF, Supporting Information
  • Wender, P. A.; Gulledge, A. V.; Jankowski, O. D.; Seto, H. "Isoapoptolidin: Structure and Activity of the Ring-Expanded Isomer of Apoptolidin"Organic Letters, 2002, 4, 3819-3822. Abstract, PDF, Supporting Information
  • Wender, P. A.; Lippa B. "Synthesis and Biological Evaluation of Bryostatin Analogues: the Role of the A-Ring" Tetrahedon Lett. 2000, 41, 1007-1011. Abstract
  • Wender, P. A.; Hinkle, K. W.; Koehler, M. F. T.; Lippa, B. "The Rational Design of Potential Chemotherapeutic Agents: Synthesis of Bryostatin Analogues" Med. Res. Rev. 1999, 19, 388-407. Abstract, PDF
  • Wender, P. A.; Koehler, M. F. T.; Wright, D. L.; Irie, K. "Mapping Phorbol Ester Binding Domains of Protein Kinase C (PKC): the Design, Synthesis and Biological Activity of Novel Phorbol Ester Dimers" Synthesis 1999, 1401-1406.
  • Wender, P. A.; Debrabander, J; Harran P. G.; Jimenez J. M.; Koehler M. F. T.; Lippa, B; Park, C. M.; Siedenbiedel, C.; Pettit, G. R. "The Design, Computer Modeling, Solution Structure, and Biological Evaluation of Synthetic Analogs of Bryostatin 1" Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 6624-6629. Abstract, PDF
  • Wender, P. A.; Debrabander, J.; Harran, P. G.; Jimenez, J. M.; Koehler, M. F. T.; Lippa, B.; Park, C. M.; Shiozaki, M."Synthesis of the First Members of A New Class of Biologically Active Bryostatin Analogues" J. Am. Chem. Soc. 1998, 120, 4534-4535. PDF, Supporting Information